Fig. 6

CD133 CAR-T and PD-1 s cells eliminate tumour cells in a Hep3B metastatic and in situ xenograft tumour mouse models. A Schematic diagram of CAR-T cell treatment. In brief, NCG mice were intravenously injected with 2.5 million Hep3B-luc cells. Metastasis was confirmed by bioluminescence imaging, and the groups were then treated with a tail veil injection of 5 million Mock T, CD133 CAR-T, or CD133 CAR-T and PD-1 s cells 55 days after inoculation. B Bioluminescence imaging of Mock T cell-, CD133 CAR-T cell- or CD133 CAR-T and PD-1 s cell-treated groups in a metastatic model of HCC. C The growth curves of the Mock T cell-, CD133 CAR-T cell- and CD133 CAR-T and PD-1 s cell-treated groups are shown in Fig. 6B. Mean ± SD, n = 3, two-tailed unpaired Student’s t test, **P < 0.01, ns, not significant. D Schematic diagram of CAR-T cell treatment. In brief, 2.5 million Hep3B-luc cells were injected into the livers of NCG mice. The tumour was confirmed by bioluminescence imaging and then treated with a tail veil injection of 5 million Mock T, CD133 CAR-T or CD133 CAR-T and PD-1 s at 22 days after inoculation. E The bioluminescence imaging of Mock T cell-, CD133 CAR-T cell- or CD133 CAR-T and PD-1 s cell-treated groups in an situ xenograft tumour model of HCC. Mean ± SD, n = 5, two-tailed unpaired Student’s t test, *P < 0.05, ns, not significant. F, G The total flux and the metastasis flux of the Mock T cell-, CD133 CAR-T cell- and CD133 CAR-T and PD-1 s cell-treated groups in Fig. 6E. Mean ± SD, n ≥ 2, two-tailed unpaired Student’s t test, **P < 0.01, ns, not significant. H The bar graph shows the frequency of CAR-T cells 16 days after the last instance of Mock T, CD133 CAR-T and CD133 CAR-T and PD-1 s cell therapy identified by flow cytometry using anti-human CD3